has signed a definitive merger agreement to be acquired by

Contact Us

On May 4, 2021, Chiasma, Inc. (NASDAQ: CHMA), a Newton, Massachusetts-based biopharmaceutical company, signed a definitive merger agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, in an all-stock deal.

Duff & Phelps, A Kroll Business, served as a financial advisor to the board of directors of Chiasma and provided an independent fairness opinion in connection with the transaction.

About Chiasma, Inc. (NASDAQ: CHMA)
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. Goodwin Procter LLP served as legal counsel to Chiasma.

About Amryt Pharma plc (NASDAQ: AMYT, AIM: AMYT)
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Gibson, Dunn & Crutcher LLP served as legal counsel to Amryt.

2021-05-10T00:00:00.0000000 /-/media/assets/images/transactions/2021/chiasma-inc.png /-/media/assets/images/transactions/2021/amryt-pharma.png /en/transactions/fairness-opinions/fairness-opinion-chiasma-inc case study {CA601B88-1E91-4803-A6A4-ECC35D220DCC} {E2BFF9A8-DC11-4262-ADBB-D1B589EEAD42} {170088C8-830B-4C38-BC1D-E375A677EEDC} {22071366-6F45-4C04-8261-CDFA24749510} {A60877A4-2248-456C-B8DE-728B8C4124FC} {2DEEE4D2-8278-4C50-B3FF-1563BB257804}

Stay Ahead with Kroll

Corporate Finance

M&A Advisory

Middle-market M&A advisory differentiated by industry expertise and superior deal execution.

M&A Advisory
Transaction Advisory Services

Transaction Advisory Services

Seamless analytical advisory through the deal continuum, from transaction origination to closing.

Transaction Advisory Services

Insights

M&A Advisory

European Chemicals Update – Q4 2021

M&A Advisory
Cyber

Insider Threat Indicators and Detection: When Employees Turn Ransomware Accomplices

Cyber
Cyber

The THIP Model: Embedding Emotional Intelligence in Third-Party Risk Management

Cyber

News